Journal article
gyrA Mutations in Mycoplasma genitalium and Their Contribution to Moxifloxacin Failure: Time for the Next Generation of Resistance-Guided Therapy
GL Murray, EL Plummer, K Bodiyabadu, LA Vodstrcil, JL Huaman, JA Danielewski, TP Chua, DA Machalek, S Garland, M Doyle, EL Sweeney, DM Whiley, CS Bradshaw
Clinical Infectious Diseases | OXFORD UNIV PRESS INC | Published : 2023
DOI: 10.1093/cid/ciad057
Abstract
Background: Although single nucleotide polymorphisms (SNPs) in Mycoplasma genitalium parC contribute to fluoroquinolone treatment failure, data are limited for the homologous gene, gyrA. This study investigated the prevalence of gyrA SNPs and their contribution to fluoroquinolone failure. Methods: Samples from 411 patients (male and female) undergoing treatment for M. genitalium infection (Melbourne Sexual Health Centre, March 2019-February 2020) were analyzed by Sanger sequencing (gyrA and parC). For patients treated with moxifloxacin (n = 194), the association between SNPs and microbiologic treatment outcome was analyzed. Results: The most common parC SNP was G248T/S83I (21.1% of samples),..
View full abstractGrants
Awarded by Australian Research Council
Funding Acknowledgements
This work was supported by an Australian Research Council (ARC) Industrial Transformation Research Hub Grant (IH190100021, G. L. M., C. S. B., D. M. W.) and Victorian Medical Research Acceleration Fund grant (G. L. M., C. S. B.). C. S. B. and S. M. G. are supported by Australian National Health and Medical Research Council Investigator Grants (GNT1173361 and 1197951, respectively).